Friday, 16 October 2026European Markets

EIDESVIK OFFSHORE Stock Over 30% Up In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of EIDESVIK OFFSHORE (Oslo Børs All-share Index_GI: EIOF.OL) rose by a staggering 30.66% in 21 sessions from 8.97 kr to 11.72 kr at 22:27 EST on Thursday, after five consecutive sessions in a row of losses. Oslo Børs All-share Index_GI is falling 0.2% to 1,413.04 kr, after two successive sessions in a row of losses.

About EIDESVIK OFFSHORE

Eidesvik Offshore ASA operates as a shipping company in Norway. It operates through Supply, Subsea/Wind, and Seismic segments. The company delivers shipping services to customers who produce seismic data; subsea inspection, maintenance, repair, and construction services for subsea work in the oil industry; and shipping services to the offshore oil industry. It operates 8 large supply vessels; a fleet of 4 vessels related to seismic; and a fleet of 4 vessels related to subsea/wind. The company was founded in 2004 and is headquartered in Bømlo, Norway. Eidesvik Offshore ASA operates as a subsidiary of Eidesvik Invest AS.

Earnings Per Share

As for profitability, EIDESVIK OFFSHORE has a trailing twelve months EPS of -1.99 kr.

Volume

Today's last reported volume for EIDESVIK OFFSHORE is 160822 which is 94.55% above its average volume of 82587.

More news about EIDESVIK OFFSHORE (EIOF.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com